Lab-Grown immune cells take on head and neck cancer
NCT ID NCT06236425
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new approach for advanced head and neck cancer that has stopped responding to standard treatments. Doctors take a patient's own tumor-fighting immune cells (TILs), grow more of them in a lab, and give them back along with the immunotherapy drug Keytruda. The study includes only 7 patients and focuses on safety, not yet on effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TBio-4101 (a patient's own immune cells grown in a lab) plus pembrolizumab (Keytruda) with or without chemotherapy
- What this could lead to
- If it works, this could point toward a new treatment option for advanced head and neck cancer that has stopped responding to standard therapy.
- What could go wrong
- This is a very early, small safety study with only 7 patients. The treatment involves strong chemotherapy and immune-boosting drugs, which can cause serious side effects. Success is uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Smartphone app aims to combat malnutrition in head and neck cancer patients
- Can adding radiation boost immunotherapy against spread head and neck cancer?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- New hope for hard-to-treat cancers? experimental combo enters phase 2 trial
- Morning or afternoon? new study tests if immunotherapy timing boosts cancer fight